Product Details

Identify heart failure decompensation, increase CRT response, reduce costs, and improve quality of life in heart failure patients with our RESONATE family of implantable CRT-Ds (cardiac resynchronization therapy defibrillators).

• Boston Scientific devices are unique by providing 8 shocks in the VF zone, the option to choose shock polarity, and automatically invert shock polarity in a series of shocks
• HeartLogic™ Heart Failure Diagnostic can predict heart failure events weeks in advance with minimal alerts2
• SmartCRT™ Technology provides customized programming to obtain CRT response in most patients3
• EnduraLife™ Battery Technology extends device longevity (up to 13.2 years even with MultiSite Pacing turned on)* 
• RightRate™ Minute Ventilation is the only sensor clinically proven to restore chronotropic competence4 (available only in RESONATE HF) 

Download the RESONATE ICD & CRT-D informational brochure

 

Watch the video below to discover the innovation behind the RESONATE™ family of ICDs and CRT-Ds EasyView™ Header & Feedthrough System —engineered for precision, durability, and seamless integration. The system preserves the electrical isolation of the lead wires as they pass into the internal circuitry while concurrently maintaining the hermeticity of the pulse generator.

 

Clinical Data

MANAGE-HF trial

Investigated the clinical integration and safety of the FDA-approved HeartLogicTM Heart Failure Diagnostic in the management of patients with heart failure9:

• HeartLogic was safely integrated into clinical care
• Early treatment augmentation was associated with more rapid recovery of the HeartLogic index compared to patients with no change in treatment following an alert
• 67% reduction in heart failure hospitalizations compared to pre-study9

Read the MANAGE-HF clinical trial summary 

 

 

SMART-MSP trial

The SMART-MSP clinical trial exceeded both its end points:

• Safety Endpoint: The MultiSite Pacing (MSP) feature-related complication-free rate at 180 days post MSP on is 99%
• Effectiveness Endpoint: 51% of the non-responders at 6 months converted to responders at 12 months3

Read the SMART-MSP clinical trial summary

 

NAVIGATE X4 trial

The NAVIGATE X4 trial was a prospective, non-randomized, multi-center, single-arm, clinical study. With 764 patients in 88 implant centers.

• 50% of ACUITY X4 leads were placed in 6 minutes or less and required no reoperations due to pacing capture or thresholds
• 77.3% of ACUITY X4 Spiral leads were programmed with a proximal electrode as the pacing cathode5

Read the NAVIGATE X4 clinical trial data

 

Preventing sudden cardiac death

The number one reason these devices are implanted is to prevent sudden cardiac death and Boston Scientific has provided meaningful shock features since 1995.  All transvenous ICDs and CRT-Ds available to implant provide 8 shocks in the VF zone, safely support programmable shock polarity, and automatically invert polarity in a series of shocks.  This video highlights these features.

 

 

Storm Aborted by Automated Shock Polarity Reversal in ICD

Read the HeartRhythm Case Reports article: Storm Aborted by Automated Shock Polarity Reversal in ICD.

 

More shocks when conversion is difficult

Large clinical trials show the mortality benefit of ICDs is a result of successful shocks.15,16

Among leading manufacturers, shock efficacy is nearly identical for shocks 1-6 with .46% and .42% of adjudicated VT/VF episodes reaching the 6th shock.13,14

However, Boston Scientific devices provide 8 shocks in the VF zone while others only provide 6.

Why is this important? One in 142 patients needed more than 6 shocks to convert anepisode of VT/VF.13

 

Real-world examples

See the value of Boston Scientific features to prevent sudden cardiac death in these real-world examples.

 

Spontaneous VF converted on 8th shock in Reversed polarity.

 

Initial polarity shock successfully converts induced VF after Reversed polarity shock failed.

 

Induced VF converted via Reversed polarity shock after Initial polarity shock failed.

 

 

How we compare to our competitors

The 8-year product performance reports show that CRT-Ds with EnduraLife Technology have greater longevity than comparable devices.6-8

Boston Scientific

CRT-Ds still in service6

Medtronic

 Viva™ XT CRT-Ds7 still in service

Medtronic

Viva Quad XT CRT-D8

Key features

RESONATE X4 and RESONATE HF are Boston Scientific’s most technically advanced CRT-Ds available with the following features:

HeartLogic Heart Failure Diagnostic, SmartCRT Technology, EnduraLife Battery Technology, ImageReady MR-Conditional Systems, and RightRate Minute Ventilation (available only with RESONATE HF).

 

HeartLogic Heart Failure Diagnostic

Predict potential heart failure events weeks in advance with HeartLogic.

Personalize cardiac care using the patient’s response to arrhythmic and pacing changes. Studies with HeartLogic devices have resulted in 67% reduction in heart failure related hospitalizations.9

Learn more about HeartLogic

SmartCRT Technology

Personalize CRT therapy to each patient for the most optimized outcomes.

SmartCRT helps you maximize patient response to CRT therapy by optimizing where, when, and how to pace.  

Learn more about SmartCRT

RightRate Minute Ventilation

The only sensor clinically proven to restore chronotropic competence and maintain healthy heart rate variability.10

RightRate dual sensor adapts to changes in movement and respiration, regulating the patient’s ability to increase their heart rate during exercise or other everyday activities. It’s directly correlated with the patient’s breathing instead of relying on an accelerometer only. 

Available only with RESONATE HF CRT-D. 

Learn more about RightRate

EnduraLife Battery Technology

Industry-leading longevity without compromising patient care.

CRT-D devices with EnduraLife have up to 13.3 years projected longevity*, giving you the clinical freedom to make programming decisions that optimize therapy for the patient, not the device.

Fewer major complications. Better for patients. 

Learn more about EnduraLife

ImageReady MR-Conditional Systems

ImageReady MR-Conditional systems make MRIs possible for heart failure patients.†

Patients can safely get Full Body MRI scans at 1.5T or 3T with ImageReady MR-Conditional devices without exclusion zone, scan duration, or patient height restrictions.11,12

ImageReady is compatible with the RESONATE X4 and RESONATE HF CRT-Ds. 

Learn more about ImageReady

Product specifications

Mechanical specifications

Model	Type	Size (cm) (W x H x D)	Mass (g)	Volume (cc)	Connector Type (RA RV LV)
G547 (HF)	X4 CRT-D	5.37 x 8.18 x 0.99	73.8	32.5	RA: IS-1; RV: DF4; LV: IS4
G447	X4 CRT-D	5.37 x 8.18 x 0.99	73.8	32.5	RA: IS-1; RV: DF4; LV: IS4

 

Longevity Information

The following tables represent sample pulse generator life expectancy estimation (implant to explant) with EnduraLife batteries as provided in product labeling. For specific programmable parameter ranges, refer to product labeling at www.bostonscientific-elabeling.com, or contact Boston Scientific technical services or your local representative.

Projected longevitya	Ventricular Chambers	RA/RV	LV	LVbd	500Ω with LATITUDE™b	700Ω with LATITUDE™b	700Ω no LATITUDE™, RS, or HFSSc
MultiSite Pacing Off
Typical programmed setting	BiV	2.5 V	3.0 V	Off	9.7	10.5	11.3
Maximum labeled longevity	LV-Only	2.0 V / Off	2.0 V	Off	12.9	13.2	14.7
MultiSite Pacing On
Typical programmed setting	BiV MSP	2.5 V	3.0 V	3.0 V	8.2	9.1	9.7
Maximum labeled longevity	LV-Only MSP	2.0 V / Off	2.0 V	2.0 V	11.5	12.1	13.3

• Assumes 70 PPM LRL; DDDR mode; 0.4 ms Pulse Width (RA, RV, LV); sensors On, Heart Failure Sensor Suite On.
• Projected longevity is calculated assuming 2 maximum energy charging cycles per year, including automatic capacitor reforms and therapeutic shocks. These calculations also assume 3-channel EGM Onset is on and that the pulse generator spends 3 months in Storage mode during shipping and storage.

a. Assumes ZIP telemetry use for 2 hours at implant and for 40 minutes annually for in-clinic follow-up checks.

b. Assumes standard use of the LATITUDE™ Communicator as follows: Daily Device Check on, quarterly scheduled remote follow ups, and other typical interrogations.

c. Assumes LATITUDE™ Communicator is not used, Respiratory Sensor is Off, and Heart Failure Sensor Suite is Off.

d. Applies to models with MultiSite Pacing (MSP). 

 

Additional Longevity Information

• Boston Scientific devices have corporate warranties at 6 years in available geographies. Warranty information available at www.bostonscientific.com/warranty.
• Devices use Li/MnO2 chemistry.
• The Usable Battery Capacity is 1.9 Amp-hours (typical implant to battery capacity depleted).
• Shelf life is 2 years (before use by date).

 

Ordering information

Model	Description
G547	RESONATE™ HF CRT-D
G447	RESONATE™ X4 CRT-D

Reimbursement

C-Code: C1882

See all reimbursement resources

Education and training

Educational Resources
Explore CRT-D training and resources, best practices modules, medical training, and continuing education courses.

Register for EDUCARE

Resources

RESONATE CRT-D Indications, Safety and Warnings

Top

References:

1 Williams J, et al. Modeling Long-term Effect of Biventricular Defibrillator Battery Capacity on Major Complications and Costs Associated with Replacement Procedures. Poster presented at: 2021 Heart Rhythm Society; July 2021; Boston, MA.

2 Boehmer JP, Hariharan R, Devecchi FG, et al. A Multisensor algorithm predicts heart failure events in patients with implanted devices: results from the MultiSENSE study. JACC Heart Fail. 2017 Mar;5(3):216-25

3 Saba S, et al. Safety and Effectiveness of Multi-Site Pacing in Initial Non-Responders to Conventional Cardiac Resynchronization Therapy. LBCT presented at: 2021 Heart Rhythm Society; July 2021; Boston, MA

4 Chronotropic competence is defined by the Model of the Cardiac Chronotropic Response to Exercise. Wilkoff B, Corey J, Blackburn G. A mathematical model of the cardiac chronotropic response to exercise. J Electrophysiol. 1989 June;3(3):176-80.

5 Clinical Summary: NAVIGATE X4 Study 358487-022 EN US 2016-01

6. Boston Scientific Q4 2023 Product Performance Report survival probability including depletions and malfunctions of DYNAGEN/INOGEN/ORIGEN CRT-D at 8 years approved in the US April 2014, page 14, available online at www.BostonScientific.com/ppr.

7. Medtronic CRM Product Performance Report survival probability including normal battery depletion of, DTBA1BD1 Viva XT CRT-D at 8 years and market released on 29 January 2013, Medtronic product performance as of 1 December 2023, available online at https://wwwp.medtronic.com/productperformance/. Viva is a trademark of Medtronic and its affiliates.

8. Medtronic CRM Product Performance Report survival probability including normal battery depletion of, DTBA1QQ Viva Quad XT CRT-D at 8 years and market released on 3 July 2014, Medtronic product performance as of 1 December 2023, available online at https://wwwp.medtronic.com/productperformance/. Viva is a trademark of Medtronic and its affiliates.

9 Hernandez AF, Albert N, Allen L, et al. Multiple cardiac sensors for management of heart failure (MANAGE-HF) Phase I results. Abstract presented at: European Society of Heart Failure 2021 World Congress on Acute Heart Failure: June 29-July 1, 2021. Virtual. https://onlinelibrary.wiley.com/doi/epdf/10.1002/ejhf.2297 (Pg 159)

10 Chronotropic competence is defined by the Model of the Cardiac Chronotropic Response to Exercise. Wilkoff B, Corey J, Blackburn G. A mathematical model of the cardiac chronotropic response to exercise. J Electrophysiol. 1989 June;3(3):176-80.

11 Reference ImageReady MRI Technical Guide

12 Only when Conditions of Use are met

13. Cha YM, Hayes DL, Asirvatham SJ, Powell BD, Cesario DA, Cao M, Gilliam FR 3rd, Jones PW, Jiang S, Saxon LA. Impact of shock energy and ventricular rhythm on the success of first shock therapy: the ALTITUDE first shock study. Heart Rhythm. 2013 May;10(5):702-8. doi: 10.1016/j.hrthm.2013.01.019. Epub 2013 Jan 19. PMID: 23337541.

14. Medtronic White Paper, Determining the Efficacy of Monophasic Shocks, https://www.hrsonline.org/documents/medtronic-white-paperdetermining- efficacy-reduced-energy-monophasic-shocks/download.

15. G.H. Bardy, K.L. Lee, D.B. Mark, et al., for the SCD-HeFT Investigators. Amiodarone or an ICD for congestive heart failure: N Engl J Med, 352 (2005), pp. 225-237

16. Moss AJ , Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883 *Assumes 70 PPM LRL; DDDR mode; 0.4 ms Pulse Width (RA, RV, LV); sensors On, Heart Failure Sensor Suite On.

†When conditions of use are met.